The PCDx test provides patients and physicians with a blueprint of the underlying mechanisms of a patient’s disease, potential treatment approaches, and comprehensive inventory of relevant clinical trials.  It identifies actionable classes of genomic alterations in hundreds of cancer-related genes, including:

DNA Mutations

Changes in the DNA sequence of chromosomes, including insertions, deletions and base substitutions. Somatic mutation analysis has become standard of practice for solid tumors in order to identify therapeutic sensitizing and resistance mutations (e.g., EGFR, KRAS, BRAF).

Copy Number Variations (CNV)

CNVs are alterations of the DNA of the cancer genome that result in the cell having abnormal copies of one or more sections of the DNA. These alterations can have a significant impact on response to therapy (e.g., HER2).

mRNA Expression

Gene expression is the process by which information from a gene is used in the synthesis of a functional protein. Sequencing-based mRNA analysis enables the significant multiplexing of biomarker targets (e.g., ER, ERCC1).

Protein Expression

Changes in the protein expression as measured by IHC has been utilized for many years as the gold-standard to quantitate the actual translation of altered gene products. Our ability to interrogate key protein markers (e.g. PD-L1, HER2, AR, MGMT, TOP1) provides insights on potential response to both cytotoxic agents as well as emerging clinical trials


Fusions and isoforms are rearrangements of genes or the exons within genes that result in abnormal gene expression or function. These alterations can have significant impact on therapy, particularly in non-small cell lung cancers. PCDx precisely identifies the exact breakpoints with single-base resolution.

Tumor Mutation Burden

TMB is to look at the rate of mutations with the assumption that more mutations increase likelihood of an immunogenic mutation being present. The larger a region is sequenced, the more accurate TMB is. Immunotherapy pharmaceutical companies recommend at least 0.7 million bases for accurately detecting TMB. PCDx sequences ~1 million bases: Well above Pharma comanies recommendation.




PCDx is Fast

Paradigm promises a clinically relevant turnaround time. Customers can expect 5 business days from sample receipt to reporting ensures continuity of clinical care.

PCDx is Accurate

Comprehensive NGS results on as little as 1-2 slides (+ 1 slide for H&E + 1 slide per IHC)

PCDx is Effective

Looks at biomarkers associated with >90 FDA approved therapies and 24 combinations.



Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.


Through Next-Gen Sequencing (NGS), and other biomarker analysis, the Paradigm Cancer Diagnostic (PCDx) test is able to provide the treating clinician with information about the genomic and proteomic landscape of a patient’s cancer, helping personalize each patient’s course of treatment.